S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Best Bear Market Funds: Top 3 Investment Options to Consider
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
Merck, Cintas rise; GameStop, MiMedx fall, Wednesday, 3/27/2024
NASDAQ:CLOV

Clover Health Investments (CLOV) Stock Price, News & Analysis

$0.79
+0.01 (+1.28%)
(As of 03/27/2024 ET)
Today's Range
$0.78
$0.81
50-Day Range
$0.73
$1.02
52-Week Range
$0.71
$1.63
Volume
4.98 million shs
Average Volume
14.24 million shs
Market Capitalization
$392.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.50

Clover Health Investments MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
89.2% Upside
$1.50 Price Target
Short Interest
Bearish
9.60% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.11mentions of Clover Health Investments in the last 14 days
Based on 10 Articles This Week
Insider Trading
Acquiring Shares
$100,010 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.20) to ($0.16) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.22 out of 5 stars

Medical Sector

563rd out of 939 stocks

Hospital & Medical Service Plans Industry

9th out of 11 stocks

CLOV stock logo

About Clover Health Investments Stock (NASDAQ:CLOV)

Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company through its Clover Assistant, a software platform that provides preferred provider organization and health maintenance organization health plans for medicare-eligible consumers. It also focuses on non-insurance businesses. The company was incorporated in 2014 and is based in Franklin, Tennessee.

CLOV Stock Price History

CLOV Stock News Headlines

$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
CLOV Mar 2024 2.000 call
CLOV Mar 2024 2.000 put
27 show home tricks and how to spot them
Q4 2023 Clover Health Investments Corp Earnings Call
Clover Health Q4 2023 Earnings Preview
Clover Health Investments's Earnings Outlook
Clover Health Investments A earnings: here's what Wall Street expects
CLOV Mar 2024 0.500 call
CLOV Mar 2024 0.500 put
See More Headlines
Receive CLOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clover Health Investments and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Hospital & medical service plans
Sub-Industry
N/A
Current Symbol
NASDAQ:CLOV
Fax
N/A
Employees
656
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.50
High Stock Price Target
$1.50
Low Stock Price Target
$1.50
Potential Upside/Downside
+89.2%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-213,360,000.00
Pretax Margin
-10.49%

Debt

Sales & Book Value

Annual Sales
$2.03 billion
Book Value
$0.59 per share

Miscellaneous

Free Float
387,219,000
Market Cap
$392.76 million
Optionable
Optionable
Beta
1.85
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Vivek  GaripalliMr. Vivek Garipalli (Age 45)
    Co-Founder & Executive Chairman
  • Mr. Andrew Toy (Age 45)
    Co-Founder, CEO & Director
    Comp: $1.01M
  • Mr. Brady Priest J.D. (Age 47)
    Chief Executive Officer of Home Care
    Comp: $587.36k
  • Mr. Terrence Ronan (Age 64)
    Interim CFO, Principal Financial Officer & Principal Accounting Officer
  • Mr. Conrad Wai (Age 43)
    Chief Technology Officer
  • Mr. Derrick L. Nueman
    Head of Investor Relations & Corporate strategy
  • Ms. Wendy Richey
    Chief Compliance Officer
  • Ms. Karen Soares
    General Counsel, Senior VP & Corporate Secretary
  • Ms. Rachel Fish
    Chief People Officer
  • Ms. Jamie L. Reynoso (Age 54)
    Chief Executive Officer of Medicare Advantage
    Comp: $461.74k

CLOV Stock Analysis - Frequently Asked Questions

Should I buy or sell Clover Health Investments stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Clover Health Investments in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" CLOV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLOV, but not buy additional shares or sell existing shares.
View CLOV analyst ratings
or view top-rated stocks.

What is Clover Health Investments' stock price target for 2024?

1 brokers have issued 12-month price objectives for Clover Health Investments' stock. Their CLOV share price targets range from $1.50 to $1.50. On average, they anticipate the company's stock price to reach $1.50 in the next twelve months. This suggests a possible upside of 89.2% from the stock's current price.
View analysts price targets for CLOV
or view top-rated stocks among Wall Street analysts.

How have CLOV shares performed in 2024?

Clover Health Investments' stock was trading at $0.9521 on January 1st, 2024. Since then, CLOV stock has decreased by 16.7% and is now trading at $0.7930.
View the best growth stocks for 2024 here
.

When is Clover Health Investments' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our CLOV earnings forecast
.

Who are Clover Health Investments' major shareholders?

Clover Health Investments' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.99%), Vanguard Group Inc. (4.99%), Charles Schwab Investment Management Inc. (0.35%), Cubist Systematic Strategies LLC (0.24%), Northern Trust Corp (0.18%) and Swiss National Bank (0.15%). Insiders that own company stock include Anna U Loengard, Chamath Palihapitiya, Chelsea Clinton and Lee Shapiro.
View institutional ownership trends
.

How do I buy shares of Clover Health Investments?

Shares of CLOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CLOV) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners